Download Treatment failure in patients with chronic Blastocystis

1
Title- Treatment failure in patients with chronic Blastocystis infection
2
Running title- Blastocystis treatment failure
3
4
Tamalee Roberts1,2*, John Ellis2 , John Harkness1, Deborah Marriott1 and Damien Stark1
5
1
6
N.S.W, Australia
7
2
8
Ultimo, N.S.W, Australia
Department of Microbiology, SydPath, St. Vincent’s Hospital, Victoria st, Darlinghurst,
i3 Institute, School of Medical and Molecular Sciences, University of Technology, Sydney,
9
10
*
11
Vincent’s Hospital, Darlinghurst, 2010, N.S.W, Australia. Phone 61 2 8382 9209. Fax: 61 2
12
8382 2989. E-mail: [email protected]
Corresponding author. Mailing address: Tamalee Roberts, Department of Microbiology, St.
13
14
15
16
17
18
19
20
21
22
23
24
25
1
26
ABSTRACT
27
This article reports long term infection and treatment failure in 18 symptomatic
28
individuals infected with Blastocystis spp. Patients were initially treated with either
29
metronidazole, iodoquinol or triple combination therapy consisting of nitazoxanide,
30
furazolidone and secnidazole. Following treatment, resolution of clinical symptoms did not
31
occur and follow up testing revealed ongoing infection with the same subtype. Patients then
32
underwent secondary treatment with a variety of antimicrobial agents but remained
33
symptomatic with Blastocystis spp. still present in faeces. Sequencing of the SSU rDNA was
34
completed on all isolates and four subtypes were identified in this group- ST1, ST3, ST4 and
35
ST5. This study highlights the lack of efficacy of several commonly used antimicrobial
36
regiments in the treatment of Blastocystis and the chronic nature of some infections. It also
37
demonstrates the need for further research into treatment options for Blastocystis infection.
38
39
INTRODUCTION
40
Blastocystis is the most common enteric parasite present in humans (Tan et al. 2002).
41
There have been up to 14 subtypes described in humans and animals with subtype (ST) 3
42
being the predominant subtype identified in most epidemiological studies (Parkar et al. 2010;
43
Meloni et al. 2011; Forsell et al. 2012; Roberts et al. 2013). Transmission has been attributed
44
to the faecal-oral route as well as consumption of contaminated food and water (Leelayoova
45
et al. 2004). Although there is still some debate about the pathogenicity of Blastocystis,
46
symptoms attributed to Blastocystis infection include diarrhoea, abdominal pain, bloating and
47
vomiting (Boorom et al. 2008; Stensvold et al. 2009). Due to the lack of knowledge of
48
Blastocystis pathogenicity, treatment may not be offered resulting in ongoing symptoms and
49
possible transmission to family and household members. Metronidazole is the most
50
commonly prescribed drug for the treatment of Blastocystis with a large variation in efficacy
2
51
ranging from 0%- 100% (Nigro et al. 2003; Moghaddam et al. 2005; Stensvold et al. 2008).
52
Other antimicrobial agents which have been used to treat Blastocystis infection include
53
paromomycin, nitazoxanide, iodoquinol and trimethoprim- sulfamethoxazole with varying
54
results (Cimerman et al. 2003; Pasqui et al. 2004; Rossignol et al. 2005; Andiran et al. 2006).
55
In this study, 18 symptomatic patients infected with Blastocystis were followed to
56
determine the efficacy of antimicrobial treatment. We report emergence of treatment failure
57
with metronidazole involving four different Blastocystis subtypes.
58
59
METHODS
60
Stool samples were collected from 18 individuals complaining of intestinal symptoms
61
including diarrhoea, abdominal cramps and bloating. All samples were submitted to
62
microscopy of a permanent modified iron haematoxylin stain according to the manufacturer’s
63
instructions (Fronine, Australia). DNA was extracted using the Bioline Isolate fecal DNA kit
64
as per manufacturer’s instructions, and underwent PCR for the detection of Blastocystis sp.
65
using a previously described method (Stensvold et al. 2007). DNA sequence analysis was
66
performed on all PCR products generated. PCR products were purified using the QIAquick™
67
PCR purification Kit (Qiagen) as per the manufacturer’s instructions and sent to the
68
Australian Genome Research Facility (Westmead Millennium Institute, Sydney) for
69
sequencing in both directions and reads were assembled in to a consensus. The SSU rDNA
70
sequences were then compared to those available in the GenBank database using the
71
BLASTN program run on the National Centre for Biotechnology Information server
72
(http://www.ncbi.nlm.nih.gov/BLAST). Samples also underwent PCR for the detection of
73
Dientamoeba fragilis using a previously published method (Stark et al. 2010). PCR was
74
performed on all samples positive for Entamoeba histolytica complex by microscopy to
75
speciate (Fotedar et al. 2007). All samples were also screened for bacterial pathogens
3
76
including Salmonella sp, Shigella sp, Vibrio cholerae, Campylobacter sp, Clostridium
77
difficile and Aeromonas sp. Household members and pets were also screened for the presence
78
of Blastocystis.
79
RESULTS
80
Eighteen patients were identified as infected with Blastocystis spp. by microscopy and
81
confirmed by PCR. All patients were symptomatic. A total of four different subtypes (ST)
82
were identified by sequencing- ST1 (n=1), ST3 (n=14), ST4 (n=2) and ST5 (n=1). No
83
bacterial pathogens were isolated. Due to the chronic nature of infection no viral testing was
84
performed. The cohort consisted of eight females and 10 males with an average age of 37
85
years (6-62 years). Results summarised in Table 1.
86
Patients 1-3 were family members living at the same residence. Symptoms of
87
diarrhoea were described after the ingestion of water from a contaminated water tank from a
88
property in rural New South Wales, Australia. Blastocystis sp. and Dientamoeba fragilis were
89
detected by microscopy in all three patients. The patients were prescribed a dose of
90
metronidazole 400mg three times daily but remained symptomatic following treatment.
91
Follow- up testing one month post- therapy revealed that all patients were still infected with
92
Blastocystis and patient 2 was still positive for D. fragilis. Subtyping of the isolates
93
demonstrated the same subtypes were present in both the pre and post treatment samples
94
(ST5 in patient 1 and ST3 in patients 2 and 3). All three patients were then treated with
95
paromomycin (25mg/kg three times daily). Follow-up clinical consultation and subsequent
96
stool samples revealed clearance of Blastocystis (and Dientamoeba fragilis in patient 2) with
97
resolution of symptoms.
98
Patient 4 was positive for Blastocystis ST1. This patient also had E. histolytica
99
complex by microscopy which was subsequently confirmed as the non-pathogenic E. dispar
100
by PCR. The patient complained of diarrhoea, nausea and abdominal pain. Initial treatment
4
101
with metronidazole 400mg three times daily for seven days resulted in the clearance of E.
102
dispar; however Blastocystis was still present and symptoms persisted. The patient was then
103
prescribed a single dose of tinidazole but remained symptomatic and failed to clear
104
Blastocystis. Finally norfloxacin was administered for four weeks. The patient reported a
105
slight reduction in gastrointestinal symptoms and follow-up samples six months later showed
106
that while the patient was no longer symptomatic, Blastocystis was still present in the stool
107
but in very low numbers. The patient’s household contacts were tested for Blastocystis and
108
both the housemate and pet dog tested negative for Blastocystis by microscopy and PCR.
109
Patient 5 first presented with intestinal symptoms of diarrhoea and abdominal cramps
110
after travelling to Borneo. A laboratory diagnosis of Blastocystis infection was made but the
111
physician did not prescribe anti-parasitic treatment. The patients’ gastrointestinal symptoms
112
continued for 12 months. The patient was subsequently diagnosed with Blastocystis (ST4) in
113
the absence of any other pathogens. Treatment was commenced immediately with
114
metronidazole 400mg of three times daily for ten days. Three months following treatment the
115
patient was still symptomatic and follow-up samples confirmed that Blastocystis (ST4) was
116
still present. The patient was then treated with ciprofloxacin. However, one year later
117
gastrointestinal symptoms remained and the faeces was confirmed positive for Blastocystis
118
ST4 by microscopy and PCR.
119
Patient 6 had a history of abdominal cramps, vomiting, diarrhoea and bloating for
120
three years. This patient saw several gastroenterologists and was diagnosed with irritable
121
bowel syndrome without having any stool samples collected to exclude infective pathogens.
122
After another year a stool sample was finally obtained and Blastocystis ST4 was identified.
123
The patient was prescribed metronidazole 400mg three times daily. Symptoms partially
124
subsided after treatment but two years later the patient had ongoing gastrointestinal
125
symptoms and Blastocystis ST4 was still present. The patient had several animals which were
5
126
all tested for Blastocystis. One chicken was positive for Blastocystis ST2 and two guinea fowl
127
were positive for ST7.
128
Patients 7-18 were all diagnosed with Blastocystis ST3 infection after seeing a
129
gastroenterologist complaining of diarrhoea and abdominal pain. Five patients were initially
130
treated with metronidazole (400mg three times daily) for 10 days, two with iodoquinol
131
(630mg three times daily) and doxycycline (50mg twice daily) for 20 days, and five with a
132
triple therapy of nitazoxanide, furazolidone and secnidazole. After treatment all patients
133
continued to describe ongoing gastrointestinal symptoms. None of these patients owned pets
134
or had other household members complaining of gastrointestinal symptoms.
135
136
DISCUSSION
137
There is increasing debate over the pathogenicity of Blastocystis with some studies
138
stating that it is not pathogenic while others argue the validity of Blastocystis being
139
considered a pathogen (Stark et al. 2007; Tan 2008; Roberts, Stark et al. 2013). One
140
viewpoint is that some subtypes of Blastocystis may be pathogenic. This study’s results are
141
consistent with that viewpoint, as we demonstrated by the presence of chronic symptoms in
142
the absence of any other infectious agents (Hussein et al. 2008; Ozyurt et al. 2008; Roberts,
143
Stark et al. 2013). This study reports treatment failure for 18 individuals identified with
144
chronic Blastocystis infection. All patients complained of intestinal symptoms including
145
diarrhoea, abdominal cramps and nausea. All patients were infected with Blastocystis and
146
four different subtypes were identified from this group- one ST1, 14 ST3, two ST4, and one
147
ST5.
148
ST3 is the most common subtype found in most epidemiological studies and there has
149
been a low association between subtype and symptoms. There have been several previous
150
studies that have shown approximately 40- 60% of patients with ST3 have some sort of
6
151
gastrointestinal symptom (Jones et al. 2009; Jantermtor et al. 2013; Roberts, Stark et al.
152
2013). ST3 was the most common subtype isolated in this group and all patients had
153
symptoms suggesting that this subtype is pathogenic. Although four patients had other
154
parasites present on initial testing, after the first treatment these parasites were cleared while
155
intestinal symptoms still persisted. No other pathogens were identified which suggests that
156
Blastocystis was the probable cause of these symptoms.
157
The three family members that presented with Blastocystis stated that symptoms
158
started after the consumption of water from a water tank whilst on holiday in rural Australia.
159
There were four members of the family that were infected with Blastocystis but after the
160
initial treatment, one patient had resolution of symptoms and diagnostic methods confirmed
161
that infection had been cleared. There is the possibility that re-infection rather than treatment
162
failure occurred with the other three members of the family, but as two different subtypes
163
were isolated within this group and that the fourth member did not have any further
164
symptoms, this appears unlikely. It has been previously suggested that treatment failure could
165
be mistaken for re-infection. This should be considered in all cases where symptoms persist
166
(Stensvold et al. 2010).
167
Although there have been several publications that have reported the eradication of
168
Blastocystis with metronidazole, there have been few studies that have examined treatment
169
failure in relation to subtype. Metronidazole is considered first-line treatment but reported
170
success rates vary between 0%-100% (Stensvold, Smith et al. 2010). Metronidazole treatment
171
failure has been reported in one patient with ST2 related urticaria and gastrointestinal disease
172
(Vogelberg et al. 2010), a patient with severe intestinal symptoms associated with ST8
173
(Stensvold, Arendrup et al. 2008), and six ST3 and one ST1 infections in patients whom
174
presented with both urticarial and gastrointestinal symptoms (Jones, Whipps et al. 2009). A
175
study of 11 symptomatic patients (five with ST1, four ST3, four ST4 and one ST6 with three
7
176
mixed infections) treated with either metronidazole or trimethoprim/ sulfamethoxazole
177
reported that no infection was cleared by treatment (Nagel et al. 2012). The 11 patients in our
178
study who were initially treated with metronidazole were shown to have treatment failure
179
along with the other seven patients treated with combination therapy. It has previously been
180
suggested that some subtypes might be more resistant or are more likely to fail treatment than
181
others. However our study, where four different subtypes were identified, suggests that any
182
subtype could result in treatment failure. These results also highlight the fact that Blastocystis
183
should be considered a pathogen as all patients noted severe symptoms in the absence of any
184
other pathogen.
185
This study also highlights the need for other treatment options for Blastocystis
186
infection. One study has demonstrated the efficacy of Saccharomyces boulardii (250mg twice
187
a day, Reflor) (Dinleyici et al. 2010) while others have reported treatment with
188
trimethoprim/sulfamethoxazole with varying results; 22% eradication (Moghaddam,
189
Ghadirian et al. 2005), 95% clearance (Ok et al. 1999) and 100% efficacy (Stensvold,
190
Arendrup et al. 2008). Other studies suggest paromomycin is the most effective agent for
191
clearing Blastocystis with up to 100% efficacy and in our study paromomycin also appeared
192
to be effective (Armentia et al. 1993; Kick et al. 2002; Pasqui, Savini et al. 2004; Valsecchi
193
et al. 2004; van Hellemond et al. 2012). A number of other studies have highlighted the
194
variable efficacy of a number of antimicrobial agents including nitazoxanide, iodoquinol,
195
tinidazole, emetine, pentamidine, iodochlorohydroxyquine and furazolidone (Markell &
196
Udkow 1986; Romero Cabello et al. 1997; Moghaddam, Ghadirian et al. 2005; Rossignol,
197
Kabil et al. 2005; Mirza et al. 2011).
198
Both the Centre for Disease Control (CDC) and the Australian Therapeutic Guidelines
199
refer to the clinical significance of Blastocystis as controversial. The CDC recommends
200
treatment with metronidazole, trimethoprim/sulfamethoxazole or nitazoxanide, while the
8
201
Therapeutic Guidelines recommend Blastocystis is treated with tinidazole, metronidazole or
202
nitazoxanide. There is a minor comment that says that pregnant woman should be treated
203
with paromomycin. Unfortunately paromomycin is not readily available in Australia and is
204
accessed on a case by case basis via the Special Access Scheme. From this and other studies
205
it would appear that the recommended treatments should be revised and that further studies
206
are required to determine the most effective treatment options for Blastocystis infection.
207
Blastocystis should be considered a potential pathogen when in the presence of symptoms
208
and the absence of any other infectious agents. Metronidazole should no longer be considered
209
the first line treatment prescribed.
210
Host factors such as age and ethnicity may play a role in the severity and length of
211
Blastocystis infection. The average age for patients in this group was 37 with only one child
212
in the group. A previous study showed that clearance rates for Blastocystis infection increase
213
as age increases and this could be a factor in this group with almost all of the patients above
214
the age of 27 (Pipatsatitpong et al. 2012). It has previously been shown that IL-8 and IL-10
215
single nucleotide polymorphisms (SNPs) play a role in Blastocystis infection (Olivo-Diaz et
216
al. 2012). SNPs at IL-10 have shown to vary between populations and this may play a role in
217
this Australian Caucasian study group in terms of disease and clearance (Meenagh et al.
218
2002).
219
220
CONCLUSION
221
This study reports the failure of treatment to clear Blastocystis infections in 18
222
patients treated with a number of different antimicrobial agents, in particular the
223
recommended treatment agent, metronidazole. This study identified four different subtypes-
224
ST1, ST3, ST4 and ST5 and demonstrated that there is not one particular subtype that has a
225
higher rate of treatment failure. This study also highlights the pathogenic role of Blastocystis
9
226
and reasserts that it should be considered a pathogen when found in conjunction with
227
symptoms and no other infectious agents. Treatment failures highlight the need for further
228
antimicrobial testing to be performed to expand therapeutic options for the management of
229
Blastocystis when treatment failure does occur.
230
231
232
233
234
10
235
REFERENCES
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
Andiran, N., Z. C. Acikgoz, S. Turkay & F. Andiran (2006). "Blastocystis hominis--an emerging and
imitating cause of acute abdomen in children." J Pediatr Surg 41(8), 1489-1491.
Armentia, A., J. Mendez, A. Gomez, E. Sanchis, A. Fernandez, R. de la Fuente & P. Sanchez (1993).
"Urticaria by Blastocystis hominis. Successful treatment with paromomycin." Allergol
Immunopathol (Madr) 21(4), 149-151.
Boorom, K. F., H. Smith, L. Nimri, E. Viscogliosi, G. Spanakos, U. Parkar, L. H. Li, X. N. Zhou, U. Z. Ok,
S. Leelayoova other authors (2008). "Oh my aching gut: irritable bowel syndrome,
Blastocystis, and asymptomatic infection." Parasit Vectors 1(1), 40.
Cimerman, S., M. C. Ladeira & W. A. Iuliano (2003). "[Blastocystosis: nitazoxanide as a new
therapeutic option]." Rev Soc Bras Med Trop 36(3), 415-417.
Dinleyici, E. C., M. Eren, N. Dogan, S. Reyhanioglu, Z. A. Yargic & Y. Vandenplas (2010). "Clinical
efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with
Blastocystis hominis infection." Parasitol Res.
Forsell, J., M. Granlund, C. R. Stensvold, C. G. Clark & B. Evengard (2012). "Subtype analysis of
Blastocystis isolates in Swedish patients." Eur J Clin Microbiol Infect Dis 31(7), 1689-1696.
Fotedar, R., D. Stark, N. Beebe, D. Marriott, J. Ellis & J. Harkness (2007). "PCR detection of
Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii in stool samples
from Sydney, Australia." J Clin Microbiol 45(3), 1035-1037.
Hussein, E. M., A. M. Hussein, M. M. Eida & M. M. Atwa (2008). "Pathophysiological variability of
different genotypes of human Blastocystis hominis Egyptian isolates in experimentally
infected rats." Parasitol Res 102(5), 853-860.
Jantermtor, S., P. Pinlaor, K. Sawadpanich, S. Pinlaor, A. Sangka, C. Wilailuckana, W. Wongsena &
H. Yoshikawa (2013). "Subtype identification of Blastocystis spp. isolated from patients in a
major hospital in northeastern Thailand." Parasitol Res 112(4), 1781-1786.
Jones, M. S., C. M. Whipps, R. D. Ganac, N. R. Hudson & K. Boorom (2009). "Association of
Blastocystis subtype 3 and 1 with patients from an Oregon community presenting with
chronic gastrointestinal illness." Parasitol Res 104(2), 341-345.
Kick, G., F. Rueff & B. Przybilla (2002). "Palmoplantar pruritus subsiding after Blastocystis hominis
eradication." Acta Derm Venereol 82(1), 60.
Leelayoova, S., R. Rangsin, P. Taamasri, T. Naaglor, U. Thathaisong & M. Mungthin (2004).
"Evidence of waterborne transmission of Blastocystis hominis." Am J Trop Med Hyg 70(6),
658-662.
Markell, E. K. & M. P. Udkow (1986). "Blastocystis hominis: pathogen or fellow traveler?" Am J Trop
Med Hyg 35(5), 1023-1026.
Meenagh, A., F. Williams, O. A. Ross, C. Patterson, C. Gorodezky, M. Hammond, W. A. Leheny & D.
Middleton (2002). "Frequency of cytokine polymorphisms in populations from western
Europe, Africa, Asia, the Middle East and South America." Hum Immunol 63(11), 1055-1061.
Meloni, D., G. Sanciu, P. Poirier, H. El Alaoui, M. Chabe, L. Delhaes, E. Dei-Cas, F. Delbac, P. Luigi
Fiori, D. Di Cave other authors (2011). "Molecular subtyping of Blastocystis sp. isolates from
symptomatic patients in Italy." Parasitol Res 109(3), 613-619.
Mirza, H., J. D. Teo, J. Upcroft & K. S. Tan (2011). "A Rapid, High-Throughput Viability Assay for
Blastocystis spp. Reveals Metronidazole Resistance and Extensive Subtype-Dependent
Variations in Drug Susceptibilities." Antimicrob Agents Chemother 55, 637-648.
Moghaddam, D. D., E. Ghadirian & M. Azami (2005). "Blastocystis hominis and the evaluation of
efficacy of metronidazole and trimethoprim/sulfamethoxazole." Parasitol Res 96(4), 273275.
11
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
Nagel, R., L. Cuttell, C. R. Stensvold, P. C. Mills, H. Bielefeldt-Ohmann & R. J. Traub (2012).
"Blastocystis subtypes in symptomatic and asymptomatic family members and pets and
response to therapy." Intern Med J 42(11), 1187-1195.
Nigro, L., L. Larocca, L. Massarelli, I. Patamia, S. Minniti, F. Palermo & B. Cacopardo (2003). "A
placebo-controlled treatment trial of Blastocystis hominis infection with metronidazole." J
Travel Med 10(2), 128-130.
Ok, U. Z., N. Girginkardesler, C. Balcioglu, P. Ertan, T. Pirildar & A. A. Kilimcioglu (1999). "Effect of
trimethoprim-sulfamethaxazole in Blastocystis hominis infection." Am J Gastroenterol
94(11), 3245-3247.
Olivo-Diaz, A., M. Romero-Valdovinos, A. Gudino-Ramirez, J. Reyes-Gordillo, D. E. JimenezGonzalez, M. E. Ramirez-Miranda, W. A. Martinez-Flores, F. Martinez-Hernandez, A. Flisser
& P. Maravilla (2012). "Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican
patient population with irritable bowel syndrome infected with Blastocystis." Parasitol Res
111(1), 487-491.
Ozyurt, M., O. Kurt, K. Molbak, H. V. Nielsen, T. Haznedaroglu & C. R. Stensvold (2008). "Molecular
epidemiology of Blastocystis infections in Turkey." Parasitol Int 57(3), 300-306.
Parkar, U., R. J. Traub, S. Vitali, A. Elliot, B. Levecke, I. Robertson, T. Geurden, J. Steele, B. Drake &
R. C. Thompson (2010). "Molecular characterization of Blastocystis isolates from zoo animals
and their animal-keepers." Vet Parasitol 169(1-2), 8-17.
Pasqui, A. L., E. Savini, M. Saletti, C. Guzzo, L. Puccetti & A. Auteri (2004). "Chronic urticaria and
blastocystis hominis infection: a case report." Eur Rev Med Pharmacol Sci 8(3), 117-120.
Pipatsatitpong, D., R. Rangsin, S. Leelayoova, T. Naaglor & M. Mungthin (2012). "Incidence and risk
factors of Blastocystis infection in an orphanage in Bangkok, Thailand." Parasit Vectors 5, 37.
Roberts, T., D. Stark, J. Harkness & J. Ellis (2013). "Subtype distribution of Blastocystis isolates
identified in a Sydney population and pathogenic potential of Blastocystis." Eur J Clin
Microbiol Infect Dis 32(3), 335-343.
Romero Cabello, R., L. R. Guerrero, M. R. Munoz Garcia & A. Geyne Cruz (1997). "Nitazoxanide for
the treatment of intestinal protozoan and helminthic infections in Mexico." Trans R Soc Trop
Med Hyg 91(6), 701-703.
Rossignol, J. F., S. M. Kabil, M. Said, H. Samir & A. M. Younis (2005). "Effect of nitazoxanide in
persistent diarrhea and enteritis associated with Blastocystis hominis." Clin Gastroenterol
Hepatol 3(10), 987-991.
Stark, D., J. Barratt, T. Roberts, D. Marriott, J. Harkness & J. Ellis (2010). "Comparison of
microscopy, two xenic culture techniques, conventional and real-time PCR for the detection
of Dientamoeba fragilis in clinical stool samples." Eur J Clin Microbiol Infect Dis 29(4), 411416.
Stark, D., S. van Hal, D. Marriott, J. Ellis & J. Harkness (2007). "Irritable bowel syndrome: A review
on the role of intestinal protozoa and the importance of their detection and diagnosis."
International Journal for Parasitology 37(1), 11-20.
Stensvold, C. R., M. C. Arendrup, C. Jespersgaard, K. Molbak & H. V. Nielsen (2007). "Detecting
Blastocystis using parasitologic and DNA-based methods: a comparative study." Diagnostic
Microbiology and Infectious Disease 59(3), 303-307.
Stensvold, C. R., M. C. Arendrup, H. V. Nielsen, A. Bada & S. Thorsen (2008). "Symptomatic
infection with Blastocystis sp. subtype 8 successfully treated with trimethoprimsulfamethoxazole." Ann Trop Med Parasitol 102(3), 271-274.
Stensvold, C. R., H. C. Lewis, A. M. Hammerum, L. J. Porsbo, S. S. Nielsen, K. E. Olsen, M. C.
Arendrup, H. V. Nielsen & K. Molbak (2009). "Blastocystis: unravelling potential risk factors
and clinical significance of a common but neglected parasite." Epidemiol Infect 137(11),
1655-1663.
12
331
332
333
334
335
336
337
338
339
340
341
342
343
344
Stensvold, C. R., H. V. Smith, R. Nagel, K. E. Olsen & R. J. Traub (2010). "Eradication of Blastocystis
carriage with antimicrobials: reality or delusion?" J Clin Gastroenterol 44(2), 85-90.
Tan, K. S. (2008). "New insights on classification, identification, and clinical relevance of Blastocystis
spp." Clin Microbiol Rev 21(4), 639-665.
Tan, K. S., M. Singh & E. H. Yap (2002). "Recent advances in Blastocystis hominis research: hot spots
in terra incognita." Int J Parasitol 32(7), 789-804.
Valsecchi, R., P. Leghissa & V. Greco (2004). "Cutaneous lesions in Blastocystis hominis infection."
Acta Derm Venereol 84(4), 322-323.
van Hellemond, J. J., N. Molhoek, R. Koelewijn, P. J. Wismans & P. J. van Genderen (2012). "Is
paromomycin the drug of choice for eradication of Blastocystis in adults?" J Infect
Chemother.
Vogelberg, C., C. R. Stensvold, S. Monecke, A. Ditzen, K. Stopsack, U. Heinrich-Grafe & C.
Pohlmann (2010). "Blastocystis sp. subtype 2 detection during recurrence of gastrointestinal
and urticarial symptoms." Parasitol Int 59(3), 469-471.
345
346
347
348
349
13
350
Table 1. Blastocystis subtype results, treatment and household contacts for patients
Patient
Age
Subtype Symptoms
(years)
Initial
Clearance
2nd
Treatment
of
treatment
line Clearance
symptoms
Time elapsed Household
of
between
symptoms
initial
Contacts
Travel
and
and subtype
latest positive
sample
1
6
5
Diarrhoea
Metronidazole
No
Paromomycin
Yes
7mths
2 ST3
Rural N.S.W
2
44
3
Diarrhoea
Metronidazole
No
Paromomycin
Yes
7mths
1 ST5, 1 ST3
Rural N.S.W
3
16
3
Diarrhoea
Metronidazole
No
Paromomycin
Yes
7mths
1 ST5, 1 ST3
Rural N.S.W
4
31
1
Diarrhoea,
Metronidazole
No
Tinidazole,
No
4 yrs
Housemate and South East Asia
nausea
and
norfloxacin
dog both PCR
abdominal
negative
pains
5
30
4
Diarrhoea and Metronidazole
No
Ciprofloxacin
No
3yrs
No
No
-
-
4yrs
Chicken
Borneo
abdominal
pains
6
27
4
Diarrhoea,
Metronidazole
ST2, 14
nausea,
bloating
Guinea
and
fowl
ST7
abdominal
pains
7
34
3
Diarrhoea and Metronidazole
No
-
-
1yr
No
-
No
-
-
1yr
No
-
No
-
-
1yr
No
-
No
-
-
1yr
No
-
No
-
-
1yr
No
-
abdominal
pains
8
44
3
Diarrhoea and Metronidazole
abdominal
pains
9
54
3
Diarrhoea and Iodoquinol,
abdominal
doxycycline
pains
10
48
3
Diarrhoea and Iodoquinol,
abdominal
doxycycline
pains
11
49
3
Diarrhoea and Metronidazole
15
abdominal
pains
12
26
3
Diarrhoea and Metronidazole
No
-
-
1yr
No
-
No
-
-
1yr
No
-
Diarrhoea and Triple therapy- No
-
-
1yr
No
-
-
-
1yr
No
-
-
-
1yr
No
-
abdominal
pains
13
38
3
Diarrhoea and Metronidazole
abdominal
pains
14
54
3
abdominal
nitazoxanide,
pains
furazolidone,
secnidazole
15
29
3
Diarrhoea and Triple therapy- No
abdominal
nitazoxanide,
pains
furazolidone,
secnidazole
16
39
3
Diarrhoea and Triple therapy- No
16
abdominal
nitazoxanide,
pains
furazolidone,
secnidazole
17
51
3
Diarrhoea and Triple therapy- No
abdominal
nitazoxanide,
pains
furazolidone,
-
-
1yr
No
-
-
-
1yr
No
-
secnidazole
18
62
3
Diarrhoea and Triple therapy- No
abdominal
nitazoxanide,
pains
furazolidone,
secnidazole
351
17